14 results · 21ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

MTS Levofloxacin 0.002 - 32 µg/mL

FDA 510(k)
FDA Class 2 ·Microbiology

Pulmonary Function Test Kit B, 33mm VBMAX

FDA UDI
A-M SYSTEMS, LLC·00817081027693·Pulmonary Function Test Kit B, Disposable, Qty ...

mambo™ modular cervical plate system

FDA UDI
Ulrich GmbH & Co. KG·04052536164387·mambo bone screw, self-drilling, violet, Ø 3.5 ...

PRODIGY DIABETES MANAGEMENT SOFTWARE

FDA 510(k)
FDA Class 2 ·Clinical Chemistry

MODIFICATION TO INTEL HEALTH GUIDE, MODEL PHS6000

FDA 510(k)
FDA Class 2 ·Cardiovascular

DEXCOM G7 CONTINUOUS GLUCOSE MONITORING SYSTEM

FDA Adverse Event
Malfunction ·DEXCOM, INC.·Product code QBJ·July 14, 2025

BIPOLAR HEAD Ø28X46

FDA Adverse Event
Injury ·MEDACTA INTERNATIONAL SA·Product code KWY·January 16, 2019

EQUINOXE REVERSE SHOULDER COMPONENTS

FDA Adverse Event
Injury ·EXACTECH, INC.·Product code KWT·July 14, 2025

INSULIN INFUSION PUMP

FDA Adverse Event
Injury ·MEDTRONIC MINIMED·Product code OYC·October 17, 2014

2520274-2013-03624

FDA Adverse Event
Injury ·SYNTHES USA·Product code HWC·June 21, 2013

ONETOUCHPING GLUCOSEMGMTSYSTEM

FDA Adverse Event
Malfunction ·ANIMAS CORPORATION·Product code LZG·July 28, 2011

MIDAS REX MR8

FDA Adverse Event
Malfunction ·MDT POWERED SURGICAL SOLUTIONS·Product code HBC·May 9, 2025

MOTOR MR8 ELECTRIC

FDA Adverse Event
Malfunction ·MDT POWERED SURGICAL SOLUTIONS·Product code HBB·February 24, 2022

Merlin PCS Programmer software model 3330, used with Confirm Rx Insertable Cardiac Monitor (ICM), Model DM3500, Sterile. The firm name on the label of the ICM is St. Jude Medical Cardiac Rhythm Management Division, Sylmar, CA. - Product Usage: The Confirm Rx insertable cardiac monitor is designed to detect arrhythmias and wirelessly transmit data to the Merlin.net Patient Care Network. The Confirm Rx ICM is indicated for the monitoring and diagnostic evaluation of patients who experience unexplained symptoms such as: dizziness, palpitations, chest pain, syncope, and shortness of breath, as well as patients who are at risk for cardiac arrhythmias. It is also indicated for patients who have been previously diagnosed with atrial fibrillation or who are susceptible to developing atrial fibrillation.

FDA Enforcement
Class II ·Terminated·St Jude Medical, Cardiac Rhythm Management Division·January 22, 2020